Key Takeaways
- Broad-based 21% YoY revenue growth: All verticals contributed, led by a 44% surge in Trade Generics & Institutional and a 94% jump in Exports off a small base.
- Operating leverage tempered by reinvestment: EBITDA margin is expanding as scale kicks in, but the company is deliberately spending on umbrella branding, team build-out and leadership talent, which caps the pace of margin improvement.
- Injectable facility is the next growth leg: Mechanical completion is on track for September, with commercialization in Q4 FY24; the plant adds lyophilized vials and will serve all three business verticals, though the break-even timeline remains uncommitted.
- Regulatory tightening is framed as a tailwind: Management sees increased scrutiny of CDMO players as a great opportunity for established, WHO GMP-compliant players like Windlas, whose facilities are already audited ~70 times a year.
- What to watch next quarter: Mechanical completion of the injectable facility, the pace of customer site visits starting end of September, and any quantification of the Trade Generics vs Institutional revenue split that management has so far declined to provide.
Revenue Growth & Business Mix
- CDMO steady, Trade Generics surging: CDMO grew 14% YoY on new customer introductions and wallet-share expansion, while Trade Generics & Institutional grew 44% YoY, driven by Jan Aushadhi, army institutions, large hospitals and CDHS schemes.
- Exports off a small base: 94% YoY growth reflects expansion into semi-regulated markets, but management cautions that export growth is "fag ended," with most results materializing in year three, year four and beyond after a ~1.5-year gestation from dossier filing to approval.
- Customer stickiness is structural: The company has never lost a customer in 20-plus years; most contracts span five-plus years and get continually renewed, though some individual brands may be taken in-house by customers while the relationship continues.
- Product churn is normal: Big pharma customers change their product proportion every 2-3 years, which shifts Windlas' volume and product mix; additional products are added as proportions change.
- Revenue split withheld: Management declined to break out the ₹31 crores Trade Generic & Institutional revenue between its two components, calling the split confidential.
Hitesh Windlass: "We are actually very proud to say this, Sir that we have never lost a customer in the last 20 years, 20-plus years. We might have said no to a customer, but we have never really lost a customer."
Injectable Facility: Timeline, Scope & Economics
- Mechanical completion by end of Q2 FY24 (September): Commercialization expected in Q4 FY24, with process qualification and media fill activities underway in Q3.
- Scope expanded beyond original plan: The company purchased all new machinery, not used as contemplated in the prospectus, providing higher speed, throughput and automation. A lyophilized vials section was added, which is in high demand in export markets, increasing the cost versus the initial estimate.
- Commercialization path: Early commercialization will start with the Trade Generic vertical, moving injectables currently bought from outside in-house, then CDMO, with export concentration rising over subsequent years as registrations from the facility are filed.
- Break-even timeline uncommitted: Management said it is hard to say when the facility will break even, noting the company is re-entering injectables after an ~8-year gap and is conscious the facility should not have a detrimental impact on bottom lines.
- Capacity headroom built in: Space is available to add more lines just by adding machinery, with no supporting utilities work needed, allowing further capacity expansion depending on utilization.
Hitesh Windlass: "We have also added one more section, which is lyophilized vials, which is high in high demand in export markets. So, there is a cost increase compared to our initial estimate."
Margin Dynamics & Investment Posture
- Operating leverage is kicking in: Consistent margin increase is underway, but the company is strategically investing in long-term initiatives: creating an umbrella brand for Trade Generics, increasing team size, and bringing in leadership talent, all of which temper the pace of margin expansion.
- Medium-term margin target: Management expects 2% to 3% growth in the current EBITDA margin over a 3-4 year medium-term horizon, implying a gradual rather than sharp expansion.
- R&D spend steady: The company expects to continue spending ~1.5%-2% of sales on R&D annually, consistent with the prior year.
- Capex plan: ~₹40 crores will be spent phase-wise to meet the next five years' capacity needs, with regular annual capex of ₹10-₹15 crores handling the 15% de-bottlenecking.
- Working capital improving: Management said there is improvement in overall working capital days, though specific Q1 balance-sheet numbers were withheld pending limited review.
Komal Gupta: "There can be a 2% to 3% growth in the current EBITDA margin."
Trade Generics: The Blue-Ocean Bet
- Positioned as a vast, underserved opportunity: Management described the hinterland, small B-type towns, kasbas and villages as "almost a Blue ocean kind of a space," with a huge way to grow possible.
- Therapeutic differentiation from CDMO: Trade generics is usually primary care (respiratory, pain, gastro, infections), while the branded generics Windlas manufactures for CDMO customers are chronic diseases (cardiovascular, diabetes, respiratory), creating some natural separation.
- Geographic focus and expansion: The northern belt (UP, Bihar, West Bengal) with higher population density tends toward primary care; the company is expanding to richer states (South, Maharashtra) and finding opportunities in sub-chronic and chronic spaces.
- Distribution tech-enabled: Distribution software tracks all stockists, their licenses, compliance levels and stock levels; a merchandising team uses Samsung tablets with an app for live stock visibility, schemes, promotions, and can raise POs on the app.
- Working capital controlled: Working capital days for the generic business are similar to the rest of the business, which management called surprising; credit exposure to ~1,500 stockists is managed by leveraging payment-behavior history and product-movement data.
- Large pharma entry into trade generics is a net positive: If large branded generic players launch their own trade generics, their trade generics pie can get added to Windlas' CDMO vertical, working in the company's favor rather than being a competitive threat.
Hitesh Windlass: "This is almost a Blue ocean kind of a space. And we really believe that a huge way to grow is possible over here."
Regulatory & Competitive Positioning
- Regulatory tightening as a tailwind: Increased scrutiny of CDMO players due to global events is seen as a great opportunity for responsible and established players like Windlas, whose facilities already comply with WHO GMP guidelines that the regulator is now pushing others to adopt.
- Quality signaled by client base: The company serves almost all top multinationals, facilities are audited ~70 times a year, and some customers have permanent representatives in the facilities, serving as a proxy for quality standards.
- Market share ranking slipped marginally: The company moved from top 5 to top 6 in the organized category, but management said it does not know the exact reason because most competitors are unlisted and data is unavailable; some M&A activity in the industry changed the ranking slightly.
- No single-source dependency: Management denied being a de facto single-source supplier for any particular therapy or chemical, stating no Indian company would be single source in most large therapeutic segments.
- CDMO doubling ambition tied to regulatory shift: Asked about the realism of doubling CDMO revenues in five years given market growth settling at 9%-10%, management cited regulatory changes pushing compliance and a fragmented industry with quality pressures benefiting the top end; the last two quarters delivered good percent growth in CDMO despite negative volume growth in the market.
Hitesh Windlass: "See, actually, we believe this is a great opportunity for responsible and established players like Windlas. All our facilities are already complying to WHO GMP guidelines, which the regulator is now pushing and asking other industries also to step up to."
Capital Allocation & Shareholder Returns
- Share buyback completed: The ₹25 crores share buyback initiative was successfully concluded in Q1 FY24.
- Dividend policy reaffirmed: The company intends to continue paying 20% of consolidated profits as dividends, as done in FY22.
- IPO proceeds fully utilized: The entirety of ₹165 crores IPO proceeds was effectively utilized by FY23.
- Capacity expansion trigger defined: If average monthly revenue reaches ~₹50 crores, another facility will be needed; the company is actively looking for a facility that can be bought out in a nearby area and converted for usage, and is confident of being ready by the time needed.
- Small capex for quick wins: Small capex initiatives to improve capacity by 10%-15% take typically 3-4 months, providing a rapid-response lever.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectable facility mechanical completion | Mechanical completion by end of Q2 FY24 (September) | End of Q2 FY24 |
| Injectable facility commercialization | Commercialization expected, revenues thereafter | Q4 FY24 |
| EBITDA margin expansion | 2% to 3% growth in current EBITDA margin | Medium term (3-4 years) |
| Dividend payout | 20% of consolidated profits | Ongoing (as done in FY22) |
| R&D spend | ~1.5%-2% of sales annually | Ongoing |
| Capacity expansion trigger | New facility needed if average monthly revenue reaches ~₹50 crores | When trigger met |
| Capex for next five years' capacity | ~₹40 crores spent phase-wise, plus ₹10-₹15 crores annual de-bottlenecking | Next five years |
| Export revenue materialization | Most results of current filings show up in year three, year four and onwards | 3-4+ years from filing |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹145 cr, +21% YoY |
| CDMO revenue | ₹110.2 cr, +14% YoY, 76% of consolidated revenue |
| Trade Generics & Institutional revenue | ₹30.8 cr, +44% YoY, 21% of consolidated revenue |
| Exports revenue | ₹3.8 cr, +94% YoY, 3% of consolidated revenue |
| EBITDA | ₹17 cr, +24% YoY |
| EBITDA margin | 11% to 12% range over last 8-9 quarters |
| Profit after tax | ₹12 cr, +23% YoY |
| EPS | ₹5.79, +29% YoY from ₹4.50 in Q1 FY23 |
| Capacity utilization | ~50%; peak CDMO utilization globally is 60-65% |
| Revenue capacity from current facilities | ~₹600 cr; can be enhanced by 10-15% with small capex |
| R&D spend | ~₹2 cr in Q1; ~1.5% to 2% of sales annual run-rate |
| Liquidity position | ₹138 cr as on March 31, 2023 |
| Buyback completed | ₹25 cr in Q1 FY24 |
| Injectable facility capex | ~₹70 cr, up from ~₹50 cr estimated two years ago; mechanical completion expected by end of Q2 FY24 |
| Facility audits per year | ~70 times across all facilities |